Corcept Therapeutics (CORT) Earnings Date & Reports

Key Takeaways

• Corcept Therapeutics is scheduled to report second-quarter 2026 results in late July or early August, with consensus revenue estimates near $220 million and earnings per share (EPS) hovering around $0.01.
• The quarter will provide the first full reporting period capturing Lifyorli (relacorilant) commercial sales following its FDA approval for platinum-resistant ovarian cancer in March 2026.
• Investors will scrutinize whether Corcept can return to profitability after posting a net loss of $31.8 million, or $0.30 per diluted share, in Q1 2026, driven by elevated launch-related spending.
• Full-year 2026 revenue guidance of $950 million to $1.05 billion, raised in the prior quarter, sets a high bar that makes the Q2 revenue print and any guidance update pivotal for sentiment.
• Key operational metrics to watch include new patient starts for both the Cushing's syndrome franchise and Lifyorli, specialty pharmacy throughput, and selling, general, and administrative (SG&A) expense trajectory.

Earnings Context and Why It Matters

Corcept Therapeutics enters its second-quarter 2026 report at a defining juncture. The company has transformed from a single-product biopharmaceutical firm centered on Korlym for Cushing's syndrome into a multi-franchise commercial enterprise following the landmark FDA approval of Lifyorli for platinum-resistant ovarian cancer. The Q1 2026 report delivered a mixed picture: revenue grew 4.9% year-over-year to $164.9 million, but the bottom line swung deep into the red with a $31.8 million net loss as SG&A spending nearly doubled to support the Lifyorli launch. With the stock having surged over 170% year-to-date, investor expectations are elevated. The Q2 report will serve as a critical checkpoint on whether the commercial ramp can translate strategic momentum into financial results that justify the valuation.

Earnings Expectations

Wall Street analysts project Corcept will report Q2 2026 revenue of approximately $219 million to $220 million, according to consensus data from Yahoo Finance, which would represent roughly 13% growth from the $194.4 million recorded in the same quarter a year ago. On the bottom line, consensus EPS estimates range narrowly between roughly breakeven and $0.04 per share, a sharp decline from the $0.29 per share earned in Q2 2025, reflecting the significant operating expense ramp tied to the Lifyorli commercial launch. Management previously guided for a return to profitability in Q2 2026 after the Q1 loss, making the actual net income figure a central focus. Revenue upside could come from faster-than-expected Lifyorli adoption — management noted in April that over 200 physicians had already prescribed the drug within 36 days of launch — while downside risk centers on whether payor reimbursement dynamics and insurance reauthorization timelines create friction that tempers quarterly revenue recognition.

AI Screener

For investors tracking earnings season and looking to identify emerging opportunities across the pharmaceutical and biotech landscape, Tickeron's AI Screener offers a powerful, data-driven solution. This AI-powered stock and ETF discovery tool enables traders to scan thousands of securities using customizable filters — including industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven trading signals. Whether you are searching for breakout candidates, earnings-season setups, or long-term fundamental opportunities, the AI Screener helps surface actionable ideas far more efficiently than manual screening. Explore the platform to uncover stocks that align with your investment strategy and stay ahead of market-moving events.

Market Reaction and Investor Sentiment

Corcept shares have staged a remarkable rally in 2026, climbing approximately 174% year-to-date through late July to trade around $95, pushing the company's market capitalization past $10 billion. The stock received a significant boost following the Q1 2026 report in April, when management raised full-year revenue guidance to $950 million–$1.05 billion and detailed encouraging early Lifyorli launch metrics — despite the headline earnings miss and net loss. Sentiment heading into Q2 results appears cautiously optimistic; analysts maintain a consensus "Buy" rating with a median price target near $98, indicating limited near-term upside relative to current levels. Key sentiment risks include the potential for SG&A expenses to remain elevated longer than anticipated, any signs of slower Lifyorli prescription momentum, and lingering uncertainty around the Teva patent litigation related to generic Korlym. Given the stock's extended run, the bar for a positive surprise may be higher than in prior quarters.

Forward Outlook and Key Factors to Monitor

Beyond the Q2 headline numbers, several forward-looking themes will shape Corcept's investment narrative through the remainder of 2026 and into 2027.

First, the pace of Lifyorli's commercial rollout warrants close attention. Management has projected that Lifyorli could surpass $1 billion in annual U.S. revenue by the end of the decade. The Q2 report and accompanying conference call should offer updated metrics on the number of prescribing physicians, new patient starts, payor coverage wins, and any early reorder patterns that signal sustained clinical adoption. With approximately 5,000 target physicians identified, penetration rates remain a key gauge of the launch trajectory.

Second, the core Cushing's syndrome franchise is showing strong underlying demand. The specialty pharmacy transition, completed in February 2026, has allowed the company to more reliably meet prescription volume. Management has stated that March and April were record months for new patient starts. Investors should monitor whether this momentum continued through the second quarter and whether the company is adding additional specialty pharmacy partners, as previously indicated, to further expand dispensing capacity.

Third, pipeline catalysts continue to accumulate. Results from the first arm of the BELLA trial — evaluating relacorilant plus nab-paclitaxel and bevacizumab (sold by Roche as Avastin) in platinum-resistant ovarian cancer — are expected by year-end. Data from a planned pivotal Phase III trial of dazucorilant in ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease) and the Phase IIb MONARCH study of miricorilant in MASH (metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease) represent additional potential value drivers. How management frames the timing and investment requirements for these programs will influence R&D expense expectations for future quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations